Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.
Epistemonikos ID: 6417f1a64371b6d15f431185bbb42beb4934a1fb
First added on: May 15, 2024